Last reviewed · How we verify
Guideline-driven standard medical therapy
At a glance
| Generic name | Guideline-driven standard medical therapy |
|---|---|
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- AI-Based Monitoring System for Chronic Heart Failure With Advanced Wearable and Mini-Invasive Devices
- Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer (NA)
- Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD) (NA)
- Evaluation of Pharmacist Intervention for Individuals With Uncontrolled Type 2 Diabetes (NA)
- Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer and Their Family Caregivers (NA)
- StratCare Trial 2: Evaluating the Clinical and Cost-effectiveness of AI-driven Stratified Care for Depression (NA)
- Empowering Caregivers in ADHD Treatment: Standard Care Vs. Decision Aid, Coaching, and AI Support (NA)
- Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: